{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:56:27Z","timestamp":1790402187975,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":2659,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:00:00Z","timestamp":1539043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bayer AG, Berlin, Germany"},{"name":"Bayer AG, Berlin, Germany"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure (HF) is a common co-morbidity in non-valvular atrial fibrillation (NVAF) patients and a potent risk factor for stroke, bleeding, and a decreased time-in-therapeutic range with warfarin. We assessed the real-world effectiveness and safety of rivaroxaban and warfarin in NVAF patients with co-morbid HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Using US Truven MarketScan Commercial and Medicare supplemental database claims data from 11\/2011 to 12\/2016, we identified oral anticoagulant (OAC)-na\u00efve NVAF patients with HF (International Classification of Diseases, 10th Revision codes of I50 or I09.81) and \u226512 months of insurance coverage prior to the qualifying OAC dispensing. Rivaroxaban users (20 or 15 mg once daily) were 1:1 propensity score matched to warfarin users, with residual absolute standardized differences &amp;lt;0.1 being achieved for all covariates after matching. Patients were followed up until an event, OAC discontinuation\/switch, insurance disenrolment, or end of follow-up. Rates [events per 100 person-years (PYs) of follow-up] for stroke or systemic embolism and major bleeding (using the Cunningham algorithm) were compared between the matched cohorts using Cox proportion hazard regression and reported as hazard ratios (HRs) with 95% confidence intervals (CIs). We matched 3418 rivaroxaban (32% receiving the reduced dose) and 3418 warfarin users with NVAF and HF with a median (interquartile range) available follow-up of 1.4 (0.6, 2.5) years. Median age was 74 (63, 82) years, and median CHA2DS2-VASc and HASBLED scores were 4 (3, 5) and 2 (2, 3). Common HF medications included beta-blockers (64%), angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (62%), loop diuretics (46%), digoxin (11%), and aldosterone receptor antagonists (10%). The hazard of developing stroke or systemic embolism (0.98 events\/100PY vs. 1.28 events\/100PY; HR = 0.82, 95% CI = 0.47\u20131.44), ischaemic stroke (0.70 events\/100PY vs. 1.02 events\/100PY; HR = 0.77, 95% CI = 0.41\u20131.46), or major bleeding (3.86 events\/100PY vs. 4.23 events\/100PY; HR = 0.98, 95% CI = 0.73\u20131.31) was not found to be different between rivaroxaban and warfarin users. Intracranial haemorrhage was infrequent in both cohorts and numerically less with rivaroxaban (0.27 events\/100PY vs. 0.36 events\/100PY; HR = 0.73, 95% CI = 0.25\u20132.08).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Effectiveness and safety of rivaroxaban vs. warfarin are sustained in NVAF patients with co-morbid HF treated in routine practice. The general consistency between this real-world study and those from phase III randomized trial data of rivaroxaban should provide additional reassurance to clinicians regarding the use of rivaroxaban in NVAF patients with HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12365","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T12:56:30Z","timestamp":1539089790000},"page":"10-15","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness and Safety of Rivaroxaban vs. Warfarin in Patients with Non-Valvular Atrial Fibrillation and Heart Failure"],"prefix":"10.1093","volume":"6","author":[{"given":"Brandon K.","family":"Martinez","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, University of Connecticut School of Pharmacy , 69 North Eagleville Road, Unit 3092, Storrs, CT ,","place":["USA"]},{"name":"Evidence-Based Practice Center, Hartford Hospital , Hartford, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Bunz","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, New England Health Analytics, LLC , Granby, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Real-World Evidence Strategy and Outcomes Data Generation, Bayer AG , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Katharina","family":"Meinecke","sequence":"additional","affiliation":[{"name":"Real-World Evidence Strategy and Outcomes Data Generation, Bayer AG , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesh A.","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Cardiac Electrophysiology, Southcoast Health System , Fall River, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig I.","family":"Coleman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Connecticut School of Pharmacy , 69 North Eagleville Road, Unit 3092, Storrs, CT ,","place":["USA"]},{"name":"Evidence-Based Practice Center, Hartford Hospital , Hartford, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,10,9]]},"reference":[{"key":"2026012115101684500_ehf212365-bib-0001","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification of schemes for predicting stroke results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"2026012115101684500_ehf212365-bib-0002","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/STROKEAHA.116.013880","article-title":"Validation of a modified CHA2DS2-VASc score for stroke risk stratification in Asian patients with atrial fibrillation: a nationwide cohort study","volume":"47","author":"Chao","year":"2016","journal-title":"Stroke"},{"key":"2026012115101684500_ehf212365-bib-0003","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics\u20142018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"2026012115101684500_ehf212365-bib-0004","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1111\/j.1538-7836.2010.03996.x","article-title":"Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA)","volume":"8","author":"Rose","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2026012115101684500_ehf212365-bib-0005","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2009-02-207928","article-title":"Outcomes and predictors of very stable INR control during chronic anticoagulation therapy","volume":"114","author":"Witt","year":"2009","journal-title":"Blood"},{"key":"2026012115101684500_ehf212365-bib-0006","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2015.03.017","article-title":"Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry","volume":"170","author":"Pokorney","year":"2015","journal-title":"Am Heart J"},{"key":"2026012115101684500_ehf212365-bib-0007","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"key":"2026012115101684500_ehf212365-bib-0008","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012115101684500_ehf212365-bib-0009","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.113.000212","article-title":"Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF","volume":"6","author":"van Diepen","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026012115101684500_ehf212365-bib-0010","volume-title":"The Truven Health MarketScan Databases for life sciences researchers","author":"Hansen"},{"key":"2026012115101684500_ehf212365-bib-0011","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/MLR.0000000000000735","article-title":"Increased risk of readmission and in-hospital mortality using hospital administrative data: the AHRQ Elixhauser comorbidity index","volume":"55","author":"Moore","year":"2017","journal-title":"Med Care"},{"key":"2026012115101684500_ehf212365-bib-0012","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115101684500_ehf212365-bib-0013","first-page":"215","article-title":"Administrative databases and outcomes assessment: an overview of issues and potential utility","volume":"5","author":"Gandhi","year":"1999","journal-title":"J Manag Care Spec Pharm"},{"key":"2026012115101684500_ehf212365-bib-0014","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar Behav Res"},{"key":"2026012115101684500_ehf212365-bib-0015","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamacardio.2017.1883","article-title":"Effectiveness and safety of standard-dose nonvitamin K antagonist oral anticoagulants and warfarin among patients with atrial fibrillation with a single stroke risk factor: a nationwide cohort study","volume":"2","author":"Lip","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026012115101684500_ehf212365-bib-0016","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026012115101684500_ehf212365-bib-0017","doi-asserted-by":"crossref","first-page":"2D","DOI":"10.1016\/S0002-9149(02)03373-8","article-title":"Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy","volume":"91","author":"Maisel","year":"2003","journal-title":"Am J Cardiol"},{"key":"2026012115101684500_ehf212365-bib-0018","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115101684500_ehf212365-bib-0019","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2026012115101684500_ehf212365-bib-0020","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/ejhf.343","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systematic review and meta-analysis of randomized trials","volume":"17","author":"Xiong","year":"2015","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12365","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/1\/10\/66135778\/eschf_6_1_10.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/1\/10\/66135778\/eschf_6_1_10.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:13:20Z","timestamp":1769026400000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/6\/1\/10\/8403632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,9]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,10,9]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12365","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2018,10,9]]},"assertion":[{"value":"2018-05-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}